RBC Capital Maintains Outperform on Rhythm Pharmaceuticals, Raises Price Target to $155
Rhythm Pharmaceuticals, Inc.
Rhythm Pharmaceuticals, Inc. RYTM | 0.00 |
RBC Capital analyst Lisa Walter maintains Rhythm Pharmaceuticals (NASDAQ:
RYTM) with a Outperform and raises the price target from $141 to $155.